From 2014.igem.org

Revision as of 09:21, 6 July 2014

YOU SHOULD NOT SEE THIS TEXT, SLIM HEADER IS DISCONTINUED

Please change this sites template to {{Team:Aachen/Header}}

Blog #19 - Open Hardware at the Maker Faire Hannover

Michael 03:55, 6 July 2014 (CDT)

This weekend Florian, René and Michael joined Ansgar on a trip to the [http://makerfairehannover.com/ Maker Faire Hannover 2014].

The Maker Faire is an exhibition with things that people built on their own using readily available tools. Dozens of 3D printers and microcontrollers can be examined and there a lot of devices visitors can interact with. Apart from the fire-spitting dragon, our OD and fluorescence measurement devices attracted a lot of attention. We spoke with hundreds of visitors and had a lot of interesting conversations.

Saturday evening, Carsten Ludwig of the iGEM Team Braunschweig visited us. We showed him he most fascinating stands and afterwards went to the city to walk the [http://www.roterfaden-hannover.de/ Red Thread of Hannover], a track going past 36 very central tourist attractions. When the #NEDCRO soccer game started, we settled for some hamburgers, fermentation broth and exchanged funny stories about our lab experience.

On Saturday the run on our stand had been so enormous that we had to improvise and print new flyers at our hostel for Sunday, the second and last day of the fair.

Blog #18 - iGEM team at RWTH Open House

By NBailly 15:22, June 29 2014 (CDT)

Yesterday, RWTH organized an open house for students from ages 14 to 16. Different departments, institutes and student councils presented exhibits, latest research projects, and the many programs they offer. Students could actively try out science and research in prepared experiments at the each stand. Various groups of student representatives also offered first hand advice to students with respect to what to study and when and where to collect information. In presentations about the different fields of studies, students gained first insights into the world of academic professions and other career perspectives.

Our iGEM team, too, supported the bioscience department with our own stand. We presented a prototype of our measurement device Cellock Holmes that students could use to measure the fluorescence of different riboflavin solutions. Apart from giving general advice as university students to high school students, Nina and Florian explained students how they can get involved in research outside of a specific university program.

Blog #17 - Noneffective Antibiotics (Part III): Companies are Looking for Microbiologists

By NBailly 15:39, June 25 2014 (CDT)

The British-Swedish company Astra Zeneca is in a leading position. In 2012, it brought the first resistance crusher, Ceftarolin, to the European market. This drug can also cope with MRSA. Astra Zenaca, among other few pharma companies, had never given up on antibiotics research. “We have maintained our long-standing expertise of our researchers and developers on this field”, Christian Kreher says happily, who is responsible for the drug group in Germany.

Competitors, on the one hand, admit how laborious it is to still find good microbes. On the other hand, Astra Zeneca even increased its department in 2009. The corporation bought the French Novexel for 400 million dollars. There Sanofi had spun off its antibiotic research department. This way the drug pipeline of researchers from Höchst, too, ended up with the competitor Astra Zeneca.

Among the latter is another highly interesting resistance remedy of the latest generation, called Avibactam. It was combined by the Astra Zeneca developers with a classic broad-spectrum ingredient of the class cephalosporins, which rip holes into cell walls. The combined medicament is running through the last two phases of authorizing trials on humans.

The highlight of “Avi”, how expert Kreher lovingly calls his biological crowbar: It tricks persistent multi-resistant bacteria by suspending their defense against cephalosporin. This works with almost all bacteria that infect the human body. If everything works Astra Zeneca want to admit the combined drug treatment to urinary tract infections and pneumonia in 2016.

This success should sadden Sanofi researchers as well as their colleagues at the Swiss Roche and Novartis or at Bayer in Leverkusen: Years ago, they all gave up on numerous promising ideas. The at that time spun off companies Basilea in Basel, Nabriva in Vienna and Aicuris in Wuppertal now cheerfully keep on developing the concepts.

Since 2013, for example, Basilae has approval for Ceftobiprol, fifth generation cephalosporin. The special thing about it: the drug has been optimized in the lab for so long until it could cope with a multitude of killer germs at the same time. Ceftobiprol should manage them all, Basilea’s head of development Achim Kaufhold assures.

So far the innovative medicament has been admitted to help people with severe pneumonia. Since in these cases special regulations for premature stops of the therapy exist, Kaufhold could negotiate a for his company very attractive – namely a high – price with the health insurance companies. He does not want to specify any numbers but analysts estimate that the new antibiotic will yield more than one billion dollars on the market. “You really can make a lot of money will modern antibiotics”, Kaufhold, at least, is convinced.

A translation of "Wirkungslose Antibiotika" published in WirtschaftsWoche on June 23rd, 2014.

Blog #16 - Noneffective Antibiotics (Part II): Hospitals as Receptacles for Multi-Resistant Pathogens

By NBailly 17:21, June 24 2014 (CDT)

Attack and defense: that is the natural course of evolution – also in the battle between germs and drugs. Since the early days of penicillin and co. at the beginning of the 20th century, pathogens have developed strategies in order escape the antibiotics’ effect. Most antibiotics stem from molds or soil microbes that defend themselves against annoying competitors. The bacteria under siege, on the other hand, counterattack with resistances.

Antibiotics are insidious weapons: sometimes they rip holes in the cell walls of growing bacteria. Sometimes they prevent that germs secrete harmful substances which in turn kills them. Or they block the unwinding of the DNA strand so that its information cannot be read anymore. To stop the production of protein is also a strategy to hinder bacterial growth. As long as a pathogen only carries resistances against one or two of these mechanisms, it can still be attacked with a third or fourth dual mode of action. The situation just became problematic when multi-resistant germs arose: They had developed so many defense strategies that none of the hundreds of antibiotics was still effective.

Meanwhile the situation is precarious: In Europe alone about 25,000 people fall victim to multi-resistant pathogens year in and year out. Especially in hospitals, for example, when receiving an artificial hip joint, the danger to get infected with one of the main malefactors is great: the methicillin resistant Staphylococcus aureus, MRSA for short. It causes wound and abdomen infections, sepsis and pneumonia.

And even who survives a resistant germ is often hospitalized for a long time and causes on average 4,000 euros additional costs in Germany. With respect to the European Union, that adds up, including the productivity loss, to about 1.5 million euros economic damage per year.

The problem is mostly home-made, because we downright breed such resistances through the use of antibiotics with humans and animals.

A series of provisions could at least prevent that the process gains momentum and that new super bugs arise more quickly than researchers can develop new antibiotics.

After decades of slack, in which one single really new substance class with an innovative mechanism of action was brought on the market, the antibiotics research has finally come into motion again. Researchers today do not want to develop a steam roller as big as possible, that floor all kinds of bacteria, anymore. Instead, they are now looking for active ingredients that break resistances with targeted strikes.

According to Martin Blaser, this would also have another, totally different – and very positive – effect. It would lead to that we are not continuously maltreating our own, helpful bacteria, for example, in our gut. “This leads to sequential damage that we have not even anticipated yet”, the New York researcher warns.

A translation of "Wirkungslose Antibiotika" published in WirtschaftsWoche on June 23rd, 2014.

Blog #15 - Noneffective Antibiotics (Part I): Dangerous Battle against Killer Germs

By NBailly 17:06, June 23 2014 (CDT)

Are we soon going to be dying of pneumonia again? The danger exists, because most pharma groups have neglected antibiotics research for decades – and now more and more drugs fail against the killer germs.

Ice cold fog is rising. Jochen Maas and Peter Hammann carefully pull out a drawer with hundreds of plastic tubes from the almost -200°C cold liquid nitrogen tank. What the two are lifting out of a kind of deep-frozen maximum security zone in the lab of the French-German pharma company Sanofi are microbes, party more than 100 years old. The round 120,000 fungal and bacterial strains are not only an invaluable treasure for the company. Primarily, they are a sort of life insurance for human kind against constantly emerging new forms of extremely aggressive life-threatening germs.

Maas, research director of Sanofi Germany, and Hammann, who is responsible for innovation worldwide in the company, now want to retrieve this treasure. In collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology in Gießen, they are looking for modern and highly effective against bacterial infections such as pneumonia or sepsis – for new antibiotics.

Numerous of such medical ingredients have emerged from this collection. But that was a long time ago. Like almost all pharma companies, Sanofi, too, had mostly abandoned antibiotics research. There were so many, meanwhile dirt-cheap, drugs against once deadly pestilences such as syphilis and tuberculosis or against everyday infections such an inflammation of the middle ear or bladder infection. Even more critical: Companies could make more money out of cardiac and cancer treatments, that patients have to take for years, than out of antibiotics. This is because the patient mostly takes antibiotics for a few days only to get healthy again.

Meanwhile the situation has grown very acute. The all-purpose weapon antibiotic is on the verge of losing its vigor. Many pathogens have become resistant. Plagues long thought conquered come back. The experts at the World Health Organization (WHO) have already raised a loud alarm. In their recently published first global resistance report they are portraying a rather apocalyptic picture. If nothing happens, doctors soon helplessly have to watch patients die of nowadays easily curable diseases or even the smallest wound infections.

The circumstances are so extreme that even governments are investing in order to make germ defense palatable again for the pharma industry: The British pharma company GlaxoSmithKIine receives 200 million dollars from the US Ministry of Health in order to develop new resistance crushers in the upcoming five years. The European Union plans something similar with the program New Drugs for Bad Bugs.

Apart from Sanofi, other industry giants, such as Roche or Bayer, have made a face-turn and invest again in the fields of research that they had closed or demerged years ago. All of them now expect good business. In the face of this new state of emergency funds and patients at least in the wealthy part of the world are willing to pay a lot of money for effective antibiotics.

However, while it will take years until market-ready drugs arise from the now kicked off research projects of the industry giants, some few pharma and biotech companies that unperturbedly did their research, are already one step ahead. They are now already up with new or pre-commercial drugs. Big hopes rest on them now because it will depend on these new remedies whether mankind in the 21st century will not give way again to the disease-causing bacteria.

A translation of "Wirkungslose Antibiotika" published in WirtschaftsWoche on June 23rd, 2014.

Blog #14 - Students Explore Careers in Synthetic Biology

By NBailly 21:11, June 12 2014 (CDT)

Our "Synthetic Biology" teaching module has come to an end. Today was our last day at Kaiser-Karl-Gymnasium in Aachen, where we have worked together with a grade 9 biology-chemistry class for past 1 1/2 months. The students have learned about the iGEM and synthetic biology in general. We presented our project to the class, and explained various aspects for our endeavour in more detail.

To give interested students some overview of how they can get involved in synthetic biology, Vera, Florian, Ansgar and Björn gave short presentations about each university program at RWTH represented in our team: Biology, Biotechnology, Computational Engineering Science and Informatics, respectively. We gave them examples for typical classes and specialization options as well as career perspectives in each program.

While discussing some more career perspectives, we handed an evaluation sheet out to each student. This way the class could give us some feedback about our work, and leave some comments on what they liked best and what we can still improve on. On average, the students gave us an A (1,9 or 87%) for the teaching module. We are really happy about this great mark, and will try to improve on all the things the students suggested.

Unfortunately, the bell already rang when the students finished handing in their evaluation sheets. However, some students still followed our invitation to stay after class to ask more questions about paths into synthetic biology, and for some cookies.

Overall, all parties seemed really satisfied with our collaboration and we are looking forward to repeating the teaching module with other high school classes!

Blog #13 - Teaching Module Wrap-Up

By NBailly 16:32, June 05 2014 (CDT)

Today Nina and Arne discussed last class's experiment. Arne explained to the students the meaning behind the values measured, and how the students can use the value to determine the concentration of riboflavin in their vanilla pudding samples.

Subsequently, Nina explained the students how we are going to manipulate regular E. coli cells, using synthetic biology methods, to carry out the desired functions. The students also learned, what role promoters play in gene regulation, and how our iGEM team wants to regulate the expression of the genes artificially inserted into the E. coli cells.

Now we have individually discussed all aspects of our project. Therefore, Nina summarized all the topic together with the students, and outlined the link between all these different topics and our iGEM project idea. In doing so, we almost arrived at the end of our teaching module "Synthetic Biology". Next class, we will visit the biology-chemistry course of Kaiser-Karl-Gymnasium for the last time, and do some career-exploration in synthetic biology and related fields.

Blog #12 - Glowing vanilla pudding

By NBailly 16:16, June 02 2014 (CDT)

The topics of today's double lesson was quorum sensing as well as measurement of fluorescence. At the beginning of class, the students form 6 groups and start an experiment dealing with fluorescence: Each group weighs and dissolves 4g of vanilla pudding powder in 50mL of water. While conducting the experiment, each group is supervised by a member of our iGEM team.

While we give the powder some time to dissolve, René discusses the worksheet about quorum sensing that we gave out to the students last week. In doing so, the students learn what quorum sensing actually is, how it is used in different ways by a variety of bacteria, and how we want to use this function for our project.

Meanwhile the powder had dissolved in the water. Excess powder accumulated at the bottom of the beaker. Using a syringe, the students suck 2mL of supernatant out of the beaker, and press it through a filter into a cuvette. A part of our project involves the development of a fluorescence measurement device named "Cellock Holmes". Each group of students at a time places its cuvette in the "Cellock Holmes" prototype, and notes down the values displayed on the cellphone display. Of course, each group also measures the fluorescence of a positive (pure riboflavin in water) and a negative (chalk dust in water) control.

While the other groups wait for their turn, their supervisors explain the background of this experiment: The electrons in some molecules change into energy states when irradiated with electromagnetic waves. When returning to the normal state, the electrons dissipate excess energy, also in the form of electromagnetic radiation. This process is called fluorescence. Vanilla pudding contains the molecule riboflavin (vitamin B2). When riboflavin is irradiated with blue light, the molecule fluoresces green. The intensity of the green light is visually recorded by our device. Special software processes the data and the measured value is displayed on the cellphone connected to the device via Bluetooth. We will discuss the results of the experiment next class.

Blog #11 - No time for high politics

By NBailly 15:42, May 30 2014 (CDT)

International collaborations against antibiotic resistances are all well and good, but the UN Climate Change conference of all collaborations shows why coordination at the government level is the wrong approach, says Lars Fischer, editorial journalist at "Spektrum Der Wissenschaft".

Not even a century ago, the discovery of antibiotics caused a decisive turn for the better in the millennia-long battle against infectious diseases. But while many already saw pathogenic agents eradicated and a golden age of medicine seemed in reach, we have now reached an abyss: a dramatic relapse into a world looms, where microorganisms are again rulers over life and death.

The threat emanating from the increasing antibiotic resistances is existential; for every one of us, as well as the countries and society itself. That the world community unites in a supranational board in order to face the latter, suggests itself. However, as alluring as the vision of an intergovernmental panel on antimicrobial resistance, as evoked by Mark Woolhouse and Jeremy Farrar (authors of the Nature article "Policy: An intergovernmental panel on antimicrobial resistance", published May 2014), may be, this thought is gravely mistaken.

Indeed, it is right that there are parallels between climate change and antibiotic resistances, however, there are also extensive–essential–differences. Firstly, the time span: Glaciers melt over centuries, climate zones shift over centuries, the ocean level rises over millennia. That frame is very suited for the international wrestling with measures and agreements, one that often reminds outsiders of a geological process. The first bacterial resistances against a new antibiotic currently appear within a few years.

And the case of climate change is still quite simple because there is an actual scientific consensus that can be recommended to politics. Regarding antibiotic resistances, it is way more complicated. Data is lacking everywhere. The only thing that a panel like that could agree on at this moment would be a substantial need for research.

This would be a fatal signal for practice: First a big multinational panel is founded that is supposed to recommend the ultimate measures against antibiotic resistances, and then the organisation can hardly say more than "The facts are yet to be established". There is a great danger, that most stakeholders would first wait until the panel sees through its decision. And subsequently, one would still have to consolidate these recommendations at the governmental level–recommendations whose data basis is necessarily thin and incomplete. It would be easy for the profiteers of the status quo to thwart such an endeavour–just like it is happening with climate change.

Therefore, the combatants of resistances should rather avoid big politics and use the already-established networks to coordinate themselves internationally. If in doubt, influence on politics and corporations should be looked for on a local level. There are–as Woolhouse and Farrar wrote themselves–a multitude of examples for regional organisations and initiatives. Of course, such sectioned measurement structures have their disadvantages, but they are by far implemented more quickly. And the time factor is crucial: A race with bacteria has to be approached differently from one with glaciers.

A translation of "Keine Zeit für hohe Politik" published in "Spektrum der Wissenschaft" on May 30th, 2014.

Blog #10 - Microorganisms on the rise

By NBailly 16:05, May 26 2014 (CDT)

Last lesson students at Kaiser-Karl-Gymnasium took environmental samples using a variety of different contact agar plates. On the weekend, René examined the plates under the microscope and took photos. Today René and Nina present the students the results of the experiment. But first, we showed the students an excerpt from the TV show "Planetopia" that broaches the issue "Hygiene in every-day life".

Staphylo- and micrococci as well as Enterobacteria, Candida yeasts and miscellaneous fungi are found on the majority of plates. But why is there no growth on the plates containing the antibiotic? Actually, what is an antibiotic, how does it work and why are there multi-resistant pathogens? Nina explained the answer to all these questions to the students using descriptive graphics, and concluded the topic "Microorganisms in our Environment" with a short summmary.

As a starter for our next topic that is relevant to our project, we distribute a worksheet about quorum sensing among the students. For the remainder of the lesson, the students read the text and begin to answer the attached questions.

Blog #9 - Going to Munich

By AZimmermann 15:02, May 23 2014 (CDT)

Hello iGEM enthusiasts,

on the coming weekend 3 of our team (Markus, Michael and Arne) are going to travel to Munich for the iGEM meetup iGEM meets CAS. We are very excited for this and can’t wait to meet all the other teams who will be attending. Stay tuned to this blog to see the first pictures when we come back!

So stay tuned!

Blog #8 - iGEM team members back 2 school

By NBailly 16:00, May 22 2014 (CDT)

Hello iGEM enthusiasts, Since our last visit, the student of the biology-chemistry course at Kaiser-Karl-Gymnasium in Aachen have been busy studying the basics of protein biosynthesis and the "lock and key" model. Now the 9th graders are prepared to have a closer look at synthetic biology and our project.

Each year, many people die of nosocominal infections - infections that the patients acquired in a hospital. However, these infections would be preventable in large part through better hygiene programs. Diseases caused by multi-resistant pathogens are especially critical because therapy options are very limited in these cases.

But actually, what are pathogens exactly and where do they come from? In order to answer these questions, we start the teaching module with the topic "Microorganisms in our Environment". In this part, we explain which germs we encounter every day, and how be can best protect ourselves from them.

In order to demonstrate how many and which microorganisms are our steady companions, we conduct an experiment with the students. A pair of students received 3 agar plates: one with regular LB agar, one plate with agar supplemented by an antibiotic, and one selective agar plate for yeasts and fungi. Equipped with the plates, the students wander through their school and take contact samples from places they think many microorganisms grow there. We will incubate the plates over the weekend so that we can show the students in the next lesson what has grown on their samples.

Blog #7 - The Biobricks have arrived

By AZimmermann 16:02, May 12 2014 (CDT)

Hello iGEM enthusiasts,

we have finally gotten the iGEM 2014 biobricks!

Now we can really start working on the molecular side of our project.

The reveal of our project, coupled with the launch of our new website will be done by the end of next week.

So stay tuned!

Blog #6 - Preparing Cool Experiments

By AZimmermann 12:12, May 7 2014 (CDT)

Hello iGEM enthusiasts,

We are currently working together with the Kaiser-Karl-Gymnasium in Aachen. Together we are teaching the students about synthetic biology, iGEM and our project in particular. As a part of this, we are designing cool experiments for the students to do themselves. Here a some nice pictures of us preparing them:

We got a fluorescence readout!

Blog #5 - Assembly in progress

By AZimmermann 12:56, May 5 2014 (CDT)

Hello iGEM enthusiasts,

if you are like us and can't wait for our wiki page to go fully online (see last post for more information) and the project to be fully revealed, here are some pictures to tide you over until then:

Can you guess what we are assembling?

Blog #4 - We are approved!

By AZimmermann 11:00, May 4 2014 (CDT)

Hello iGEM enthusiasts,

we are more than happy to finally be able to announce that our application has been finally approved by the iGEM headquarters. Now nothing will stand between us and our journey towards the giant Jamboree at the end of October!

This will bring a few changes towards especially this site. With the approval we now have access to our own wiki website hosted on the iGEM servers. We will migrate all our previous content towards this site in the next weeks. This will include everyhting already posted on here. As soon as we have finished preparing the full migration you will automatically be redirected, so you do not need to remember a different website for all your IGEM Aachen information.

As soon as the migrations has been completed you will also find all the details you need to know about our project we have been teasing about the past weeks on facebook and twitter. So stay tuned!

The project has been progressing nicely in part due to the awesome iGEM Kits provided by NEB:

NEB you are awesome!

Also as always you can follow us on [http://www.facebook.com/iGEMAachen Facebook]] or [http://twitter.com/igemaachen Twitter]]for more information and a look behind the scenes.

Blog #3 - School Project Kick-Off

By NBailly 20:48, April 28 2014 (CDT)

Today was the kick-off for the cooperation between our iGEM team and the Kaiser-Karl-Gymnasium, a secondary school in Aachen. In the upcoming weeks, exciting school lessons with members of our iGEM team await the students of the 9th grade biology-chemistry class. Different aspects of our project will be highlighted and explained to the students. Demonstrative experiments will explain the practical relevance.

In today's lesson, our members Nina and René offered the students a short impression of what to expect in the course of this teaching module. We also explained synthetic biology and the goal of our project.

Blog #2 - The box is opened

By AZimmermann 9:46, April 28 2014 (CDT)

Hello iGEM enthusiasts,

interested to see what is inside the box from the previous post?

Guess what we are building?

Blog #1 - The opening

By AZimmermann 10:31, April 24 2014 (CDT)

Hello everyone, the iGEM competition has officially started and we are taking part! If you are as excited as we are stay tuned as we will unveil everything about our project in the upcoming weeks. This blog will function as a behind the scenes look of the project and the team. So stay tuned for everything iGEM Aachen!

In the meantime you can check us out on [http://www.facebook.com/iGEMAachen Facebook] or [http://twitter.com/igemaachen Twitter] for more updates.

This year Aachen is rocking iGEM!

YOU SHOULD NOT SEE THIS TEXT, SLIM FOOTER IS DISCONTINUED

Please change this sites template to {{Team:Aachen/Footer}}